Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

2
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (1)

Searched Name

upadacitinib

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Mirikizumab (Omvoh) for ulcerative colitis. Med Lett Drugs Ther 2024;66:46-7. [PMID: 38466213 DOI: 10.58347/tml.2024.1698c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/12/2024] Abstract Collapse Key Words Entyvio Humira Lialda Omvoh Remicade Rinvoq Skyrizi Stelara TNF inhibitors Velsipity Xeljanz Zeposia adalimumab adverse effects azathioprine dosage drug interactions efficacy etrasimod infliximab lactation mercaptopurine mesalamine mirikizumab ozanimod pregnancy risankizumab safety tofacitinib ulcerative colitis upadacitinib ustekinumab vedolizumab Collapse MESH Headings Humans Colitis, Ulcerative/diagnosis Colitis, Ulcerative/drug therapy Antibodies, Monoclonal, Humanized/adverse effects Collapse Grants Collapse Affiliation(s) Collapse
2	Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2023;65:105-112. [PMID: 37418329 DOI: 10.58347/tml.2023.1680a] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/09/2023] Abstract Ulcerative colitis (UC) and Crohn’s disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years. Collapse Key Words Apriso Asacol Azasan Azulfidine Canasa Cimzia Colazal Cortenema Cortifoam Crohn's disease Delzicol Dipentum Entyvio Humira Imuran Lialda Ortikos Pentasa Rayos Remicade Rinvoq Rowasa Simponi Skyrizi Stelara TNF inhibitors Tysabri Uceris Xeljanz Zeposia adalimumab adverse effects aminosalicylates azathioprine balsalazide budesonide certolizumab corticosteroids dosage efficacy golimumab hydrocortisone inflammatory bowel disease infliximab mercaptopurine mesalamine methotrexate natalizumab olsalazine ozanimod prednisone risankizumab safety sulfasalazine tofacitinib ulcerative colitis upadacitinib ustekinumab vedolizumab Collapse MESH Headings Humans Inflammatory Bowel Diseases/drug therapy Immunosuppressive Agents Colitis, Ulcerative Infliximab Collapse Grants Collapse Affiliation(s) Collapse